Moleculin Biotech, Inc.
MBRX evidence brief
What we can confirm
- BioSniper Score:
- 7.5 / 10
- Market Cap:
- $13.9M
- Lead Asset:
- annamycin (Phase 2/Phase 3)
What it means
What to watch
Prepared research question
What matters most for MBRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MBRX
Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on Annamycin, a next-generation anthracycline, currently conducting a pivotal Phase 2/3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (AML).
Key risk: No revenue and ongoing losses
BioSniper Score
Based on 4 of 6 signals
Market Cap
$13.9M
Cash Runway
—
Lead Asset
annamycin (Phase 2/Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for Moleculin Biotech, Inc..
Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on Annamycin, a next-generation anthracycline, currently conducting a pivotal Phase 2/3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (AML).
- Cash & equivalents of $7.3M as of 2026-06-30 [sec].
- Total revenue of $0.0M and net income of -$7.6M as of 2026-06-30 [sec].
- Shareholders' equity of $11.6M as of 2026-06-30 [sec].
- Conducting a pivotal Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine for relapsed/refractory AML [sec · filed 2026-07-31].
- Positive interim MIRACLE data showed complete remission rates three times higher than control [news · published 2026-08-14].
What works
- Annamycin is a 'next-generation' anthracycline with potential for improved safety and efficacy, including reduced cardiotoxicity [sec · filed 2026-07-31].
- Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML [news · published 2026-08-14].
- Composition of matter patent protection through 2040 with potential to extend as far as 2045, plus Orphan Drug and Fast Track designation [sec_mda · as of 2026-08-13].
What to weigh
- No revenue generated as of 2026-06-30, with a net loss of $7.6M [sec].
- Cash position of $7.3M as of 2026-06-30, though $9.3M raised after quarter-end is expected to fund operations into the first quarter of 2027 [news · published 2026-08-14].
- Dependency on third-party manufacturers for supply and manufacturing of drug candidates [sec_mda · as of 2026-08-13].
- Competition from existing therapies or new therapies that may emerge [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Annamycin is a next-generation anthracycline with potential for reduced cardiotoxicity
“We believe Annamycin is the first of its kind DNA binding agent, a "next-generation" anthracycline. Whereas first- and second-generation anthracyclines are currently used to treat approximately half of all cancers, they carry with them the burden of dangerous cardiotoxicity and efficacy limitations asso”
SEC filings · July 31, 2026
Positive interim MIRACLE data showed complete remission rates three times higher than control
“Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML”
News · August 14, 2026
Cash position and post-quarter-end raise
“Cash position, including $9.3 million raised after quarter-end, expected to fund operations into the first quarte”
News · August 14, 2026
Patent protection and regulatory designations
“Composition of matter patent protection through 2040 with the potential to extend as far as 2045 as well as Orphan Drug and Fast Track designation.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- No revenue and ongoing losses — No revenue and net loss of $7.6M as of 2026-06-30 [sec].
- Cash runway limited — Cash $7.3M as of 2026-06-30; post-quarter-end raise extends into Q1 2027 [news · published 2026-08-14].
- Dependence on third-party manufacturers — Dependency on third-party manufacturers to supply/manufacture drug candidates [sec_mda · as of 2026-08-13].
- Competition from existing/new therapies — Competition from existing therapies or new therapies that may emerge [sec_mda · as of 2026-08-13].
What to watch
- Planned 90-patient enrollment milestone in September 2026 for the MIRACLE trial [news · published 2026-08-14].
- Unblinded efficacy readout expected in December 2026 to February 2027 timeframe [news · published 2026-08-14].
- MIRACLE trial Part B initiation expected in the first half of 2027 following optimal dose selection [news · published 2026-08-14].
Sources: News · SEC filings · SEC MD&A · Generated October 5, 2026 · How we verify sources →
Run Moleculin Biotech, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Moleculin Biotech, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.82
Lead: Phase 2/Phase 3
2 candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 2.6%
- Days to cover
- 1.5
- Shares short
- 138,763
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MBRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Moleculin Biotech, Inc.?
Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on Annamycin, a next-generation anthracycline, currently conducting a pivotal Phase 2/3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (AML).
What is Moleculin Biotech, Inc.'s lead drug candidate?
Moleculin Biotech, Inc.'s most advanced tracked candidate is annamycin (Phase 2/Phase 3) for Leukemia, Myeloid, Acute.
Who is the CEO of Moleculin Biotech, Inc.?
Mr. Walter V. Klemp is the chief executive officer of Moleculin Biotech, Inc. (MBRX).
Where is Moleculin Biotech, Inc. headquartered?
Moleculin Biotech, Inc. (MBRX) is headquartered in Houston, TX, United States.
What therapeutic areas does Moleculin Biotech, Inc. focus on?
Moleculin Biotech, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.